According to a 2016 industry survey, 80% of respondents agreed that Phase I studies are becoming more complex.
Despite several years of interest, pharmaceutical companies have yet to immerse themselves in the world of EHR data integration. However, as the EHR market matures globally, the move from double data entry to EHR integration is rapidly approaching.
What role should EHR play in the future of clinical trials? My colleagues at Medidata and I spend a lot of time talking about EHR, clinical trials, and where we are headed. This post kicks off a series on EHR and clinical trials. We’re starting off with the basics. What is EHR? Because the answer is a little more complicated than it seems. And if you want to hear more, check out our EHR breakout session at Medidata NEXT Basel on March 7.
I had a lovely chat with The Telegraph's Iain Withers for an interesting article on mHealth technology to answer a pressing question: "The modern pharmaceutical age has granted doctors a panoply of drugs to help with a variety of conditions, but how to ensure the patient takes them?"
I have a short quote in the article, but I have some additional thoughts on where we are and where we are headed.